Author:
Thomas Christopher Y.,Theodorescu Dan
Publisher
Springer Science and Business Media LLC
Reference206 articles.
1. Abraham S, Knapp DW, Cheng L et al (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360
2. Ahmed S, Molife R, Shaw H et al (2006) Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle [Abstract 2076]. In: Proceeding of the American society of clinical oncology, vol 24
3. Appels NMGM, Beijnen JH, Schellens JHM (2005) Development of Farnesyl transferase inhibitors: a review. Oncologist 10:565–578
4. Bakkar AA, Wallerand H, Radvanyi F et al (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108–8112
5. Basso AD, Kirschmeier P, Bishop WR (2006) Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47:15–31
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献